Literature DB >> 2220307

Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children.

E P Calandre1, R Dominguez-Granados, M Gomez-Rubio, J A Molina-Font.   

Abstract

The Wechsler Intelligence Scales for Children was applied to 64 epileptic children and 60 healthy subjects; patients followed chronic treatment with valproic acid (n = 32) or phenobarbital (n = 32). None of the children suffered mental retardation or neurological abnormalities. The test was repeated after a 9-12 month interval: 26 of the valproate treated children and 23 of the phenobarbital-treated children performed the second evaluation. At baseline, total, verbal and performance IQ scores of children receiving phenobarbital were lower than those of controls. When the results of the first and the second tests were compared, a significant increase in IQ scores was detected among controls and patients treated with valproic acid, but not among phenobarbital-treated patients. It is concluded that long-term phenobarbital therapy induces a significant impairment in learning ability whereas long-term valproate therapy does not exert a noticeable noxious effect at this respect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2220307     DOI: 10.1111/j.1600-0404.1990.tb01008.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  17 in total

1.  The cognitive impact of antiepileptic drugs.

Authors:  Clare M Eddy; Hugh E Rickards; Andrea E Cavanna
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

Review 2.  Suicidality and antiepileptic drugs: is there a link?

Authors:  Vladimir V Kalinin
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Electroencephalogram discharges in atypical cognitive development.

Authors:  Richard E Frye; Ian Butler; David Strickland; Edwardo Castillo; Andrew Papanicolaou
Journal:  J Child Neurol       Date:  2010-03-18       Impact factor: 1.987

4.  Risk of later seizure after perinatal arterial ischemic stroke: a prospective cohort study.

Authors:  Courtney J Wusthoff; Sudha Kilaru Kessler; Arastoo Vossough; Rebecca Ichord; Sarah Zelonis; Aviva Halperin; Danielle Gordon; Gray Vargas; Daniel J Licht; Sabrina E Smith
Journal:  Pediatrics       Date:  2011-05-16       Impact factor: 7.124

5.  Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.

Authors:  Cynthia Sharpe; Gail E Reiner; Suzanne L Davis; Mark Nespeca; Jeffrey J Gold; Maynard Rasmussen; Rachel Kuperman; Mary Jo Harbert; David Michelson; Priscilla Joe; Sonya Wang; Neggy Rismanchi; Ngoc Minh Le; Andrew Mower; Jae Kim; Malcolm R Battin; Brian Lane; Jose Honold; Ellen Knodel; Kathy Arnell; Renee Bridge; Lilly Lee; Karin Ernstrom; Rema Raman; Richard H Haas
Journal:  Pediatrics       Date:  2020-05-08       Impact factor: 7.124

6.  Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes.

Authors:  Qirui Zhang; Fang Yang; Zheng Hu; Zhiqiang Zhang; Qiang Xu; Mantini Dante; Han Wu; Zhipeng Li; Qian Li; Kai Li; Guangming Lu
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

Review 7.  Antiepileptic drugs and neurodevelopment: an update.

Authors:  Susan Palac; Kimford J Meador
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

Review 8.  Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy.

Authors:  Frank M C Besag; Michael J Vasey
Journal:  Paediatr Drugs       Date:  2021-05-06       Impact factor: 3.022

Review 9.  Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors.

Authors:  Marco Mula; Michael R Trimble
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 10.  Treatment of partial seizures in childhood : an overview.

Authors:  Giangennaro Coppola
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.